ahead result preview setup segment
believ expect sequenti top-lin deceler appropri howev softer
headwind incorpor management growth guidanc combin strong
influenza season suggest top end revenu growth ep guidanc rang
top-lin consensu estim appear achiev revenu estim
oper in-lin consensu management guidanc rang
growth impli q/q deceler guidanc incorpor
headwind alari pump softwar upgrad challeng dcb comp flat
dm growth china md tender process howev management publicli reveal
discuss fda complet alari shipment return full
china md tender impact reportedli de minimu also
publicli relay influenza season provid tailwind consist cdc
data end dcb headwind like remain play paclitaxel
controversi impact anniversari management guid dcb hit
corpor wide revenu brunt expect
revenu estim like conserv driven cautiou stanc
paclitaxel risk lutonix dcb franchis result demonstr pi
portfolio new product driver off-set anoth dcb declin thu
consensu estim seem achiev bd medic estim
oper modestli aggress street estim howev
new product momentum absenc impact china md tender process
make higher consensu estim appear achiev despit highli challeng
comp final bd life scienc revenu estim
line street estim strong influenza trend plu soft influenza
comp drive out-performance momentum continu
expect rel in-lin ep perform oper margin estim
repres expans improv sg leverag cost synergi
captur partial off-set lower higher-margin dcb sale gore royalti expir
toward end increas vs compani origin deal model result
ep growth headwind tariff expect headwind
fx headwind ep growth expect factor similar
impact expect gore royalti fx china tariff headwind drive
consensu ep estim repres lsd ep declin report
basi revis adj ep penni ahead street top end
guidanc
arriv new price target assign multipl ep
estim believ share deserv modest premium mean forward price-to-earnings multipl
large-cap peer group due expect continu execut
manag team despit leadership transit well posit deliv
sustain revenu growth solid annual om expans dd
earn growth posit outlook drive reiter outperform rate
pleas see page report import disclosur
appear well posit gener sustain mid-single-digit better top-lin
growth ep growth upsid oper target via on-going stand-alone
improv contribut carefus bard rate share outperform
upsid rel formal accretion/
price pressur like continu
volum pressur like intensifi
solid execut rel expect
carefusion/bard synergi accret
target conserv
strong growth emerg market
bd guidanc prove high
bard miss accret synergi
concern strategi
becton dickinson compani bd global medic technolog compani engag
develop manufactur sale medic devic instrument system
reagent use healthcar institut life scienc research clinic laboratori
pharmaceut industri gener public
thomson one cowen compani compani file
thomson one cowen compani compani file bdx setup neutral outlook vs consensuscowen revenu estim organ consensu revenu estim organicth consensu revenu estim in-lin bdx top-line guidanc call deceler growth see guidanc rang appropri consid alari pump softwar upgrad dcb fxchalleng play although cautiou intervent unit due paclitaxel risk surround dcb franchis demonstr pi portfolio new product driver off-set lutonixdeclin strong flu season could provid tailwind china md price headwind reportedli impact importantli manag alreadi state publicli sale result like come top end guidanc rang oper margin cowen estim expans consensu neg impact price expect acut china md price headwind reportedli strengthen top-line growth expect -bdx anticip lower sale expect higher margin dcb product impact expect brunt fxheadwind neg impact top-line tailwind improv sg leverag improv expect bard cost synergi captur expect cowen estim consensu guidanc tariff impact neg fx impact neg royalti expir headwind approxim growth yearlow sale anticip growth impli deceler q/q higher share count share repurchas suspend guid share count impact start tailwind om expans guid improv fx neutral basi lower interest expens de-lever on-track gross leverag ratio end sequenti step tax rate come guid rang though expect higher vs balanc except neutral end septemb end septemb cowen
thomson one cowen compani compani file
thomson one cowen compani compani file medic setup positive-neutr outlook vs streetcowen revenu estim oper consensu revenu estim operationalchalleng comp setup combin expect headwind alari softwar upgrad flat diabet growth toughestpharm system comp drive sequenti deceler bd medic franchis tailwind new product launch provid benefit manag two public disclosur alari softwar upgrad complet ship fulli resum china md tender process zero impact bode well set rel expect guidanc rang headwindsbd medic challeng comparison diabet diabet growth expect flat tougher comp stronger-than-expect capit placement infusionpharm system face toughest comp benefit favor time custom order pattern drive sai growth md price expect headwind china tender process basic product compani wide impact primarili driven china md howev manag state publicli zero impact china md tender process headwind could still evolv move md momentum continu sequenti especi consid soft comp led vascaccess broad portfolio us/eu salesforc integr vasccar bard picc midlin busi integr cathet team drive competit conversionsnew product tailwind bd venapicc powerglidecuediabet diabet guidanc call flat growth due larg em tender order caus pull forward off-set easier comp softest driven time distributor order time tender ema launch bd nano ergonom pen needlemm continu new product momentum pyxi es launch may healthsightanalyt help off-set tougher comp driven strong infus capit placement impact alari softwar upgrad fulli resum ship dispens busi share gain respect mgmtexpect momentum continu mm except neutral forma compar end septemb end septemb cowen
thomson one cowen compani compani file
thomson one cowen compani compani file bdx life scienc setup neutral outlook vs streetcowen revenu estim oper consensu revenu estim operationalth bd life scienc segment second softest comp momentum organ along astrong flu-season bode well set expect sequenti decelcould prove conserv life scienc franchis expect deliv organ sale growth headwindspre-analyt challeng comp flu lifesciencesunit face easier y/i comp challeng stack comp experi includ flu headwind manag public commentari read suggest outsiz posit impact continu posit impact capac addit improv suppli ultratouchpush-button collect setsbd bactec platelet qualiti control media launch continu kick comp y/i strong influenza season provid nice tailwind franchis face challeng stack comp experienc kiestrainstal flu-rel headwind continu bd dd growth bd max expand menu id/ast strengthbiosci soft comp unfavor ema tender time impact instrument momentum bd facsymphoni facslyriccombin facsduet expans bd horizon brilliant dye doubl digit china bd life scienc growth expect except life neutral organ end septemb end septemb cowen
thomson one cowen compani compani file
thomson one cowen compani compani file intervent setup neutral outlook vs streetcowen revenu estim oper consensu revenu estim operationalw conserv forecast deeper impact paclitaxel coat devic includ bd lutonix franchis controversi intervent segment demonstr intervent unit abil off-set dcb soft new product portfolio driver consensu forecast impli sequenti decelin set softer y/i comp challeng stack comp view consensu estim achiev perform level headwindssurgeri toughest comp comp expect surgeri benefit gelreintroduct markethernia tougher comp benefit easier comp vs due hurrican maria on-going litig mdl southern district ohio synthet hernia mesh remain pressur peripher intervent dcb sale eros present signific headwind lutonixsal contract like remain burden pi franchis impact expect brunt fda updat guidanc remov medical-leg risk paclitaxel coat devic util easier comp paclitaxel controversi appear potenti paclitaxel impact anniversari around surgeri gelu relaunch ramp continuessal synergi biosurgeri infect control ww hemostat see strengthchloraprepchg antisept skin prep launchbiosurgeri eu sale forc product ramp rep late phasixst ovhr bioresorb hernia mesh launchesperipher intervent new product launch includ venovoven stent french av fistula system coveraav fistula cover stent continu help off-set sale eros sale mute end distribut agreement provid potenti comp relief help off-set dcbchina continu deliv consist dd growth urolog critic acut urolog new product target temp mgmtremain driver mm except intervent neutral forma compar end septemb end septemb cowen
cowen compani
thomson one cowen compani compani file bdx catalyst calendarmedicalmed deliveri solutionsbd insyteautoguardblood control gener activ safeti piv cathetersbd dispos gener activ safeti piv cathetersmed manag solut develop bd healthsightplatform offer bd healthsightclin advisor life sciencesbd high-throughput molecular system continu bd onclarityhpv assay ce-ivd markedbd high-paramet cell sorter full access facsmelodyplatform extens new new artic sun stat access wavelinqnext-gen devic caterpillar embol elev breast biopsi launch analyst day -may compani full line-up plan product launch seen next page cowen
cowen compani
thomson one cowen compani compani file bdx plan product launch cowen
figur quarterli revenu expect mm
compani report thomson eikon cowen compani
medic deliveri solut manag solut system life system system intervent critic chang good gross gross net interest expens expens incom incom tax incom oper ex-intang share estim cowen
cowen compani
mm except per share organ gener oper non-oper interest earn per cowen
cowen compani
valuat methodolog primarili base current year forward year ev/sal
ev/ebitda multipl well current year forward price-to-earnings multipl total return/p
ratio market cap/fre cash flow metric dividend yield comp
valuat methodolog primarili base current year forward year ev/sal
ev/ebitda multipl well current year forward price-to-earnings multipl total return/p
ratio market cap/fre cash flow metric dividend yield comp
competit dynam global potenti regulatori delay potenti delay
time product launch emerg develop market econom sensit
price pressur and/or weaken consum demand develop market econom
and/or polit uncertainti emerg market chang tax law outlook
dividend share repurchas fluctuat foreign exchang rate
downsid risk includ limit fail execut integr
effort includ hit synergi target engag value-destroy activ
experienc delay product develop regulatori approv face reduct
reimburs key product incur patent infring and/or product liabil
lawsuit lose market share price power due competit fail deliv
oper goal guidanc experienc macroeconom deterior
impact end market custom
